Physician profile
Kena D Lackman
NPI 1427583285
$723.26
in general payments reported to CMS, 2019-2025
19 companies · $79.52 in 2025
The $79.52 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.75 · 2022: $152 · 2023: $275 · 2024: $193 · 2025: $79.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $547.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $131.18 | 2022-2024 | |
| Lilly USA, LLC | $85.51 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $77.64 | 2022-2023 | Breztri, Farxiga |
| Exact Sciences Corporation | $71.27 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.63 | 2024-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $51.82 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.67 | 2023 | |
| Abbvie INC. | $22.80 | 2023 | |
| Neurocrine Biosciences, INC. | $22.78 | 2023 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $22.72 | 2024 | Rexulti |
| Amgen INC. | $20.77 | 2023 | Evenity, Prolia |
| Organogenesis INC. | $19.72 | 2023 | Puraply |
| Boston Scientific Corporation | $18.67 | 2024 | |
| Janssen Pharmaceuticals, INC | $18.37 | 2023 | Spravato |
| Medtronic, INC. | $16.23 | 2025 | Inceptiv |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $15.94 | 2022 | |
| Glaxosmithkline, LLC. | $13.70 | 2023 | Arexvy, Shingrix |
| Novo Nordisk INC | $13.34 | 2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kena Lackman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.